Recherche - Archive ouverte HAL

125 résultats

	Pour les 125 documents Envoyer sur ORCID RSS ATOM Exporter BibTeX XML-TEI CSV RTF EndNote PDF HTML Export avancé	Page : Page précédente 1 2 3 4 5 Page suivante	triés par Pertinence Auteur A→Z Auteur Z→A Titre A→Z Titre Z→A Date de publication croissante Date de publication décroissante Date de dépôt croissante Date de dépôt décroissante

		Infliximab concentration is predictive of control of disease activity and maintenance of treatment in rheumatoid arthritis. Lin D. Chu Miow , Emilie Ducourau , Denis Mulleman , P. Emond , Denis Ternant , et al. Annual European Congress of Rheumatology, Paris, 11-14 June 2008., Jun 2008, PARIS, France. Suppl. II:177 (THU-0131) Communication dans un congrès hal-00320106v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Adalimumab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: Can trough serum levels serve as a predictor for Future Loss of Response? K. Karmiris , Gilles Paintaud , Danielle Degenne , M. Ferrante , Anne-Claire Duveau , et al. Digestives Diseases Week San Diego 17-22 mai., May 2008, SAN DIEGO, United States. 134 (4, Supplement 1): A-68 Communication dans un congrès hal-00320142v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis Theodora Bejan-Angoulvant , David Ternant , Fadela Daoued , Frédéric Medina , Louis Bernard , et al. Arthritis & rheumatology, 2017, 69 (1), pp.108-113. ⟨10.1002/art.39841⟩ Article dans une revue hal-01980809v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial) Mario Campone , Thomas Bachelot , Isabelle Treilleux , Barbara Pistilli , Julia Salleron , et al. European Journal of Cancer, 2021, 158, pp.169-180. ⟨10.1016/j.ejca.2021.09.017⟩ Article dans une revue hal-03469622v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration Celine Desvignes , Soujanya Edupuganti , François Darrouzain , Anne-Claire Duveau , Amy Loercher , et al. Bioanalysis, 2015, 7 (10), pp.1253-1260. ⟨10.4155/bio.15.30⟩ Article dans une revue hal-02372930v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Pharmacokinetics of adalimumab in Crohn’s disease David Ternant , Konstantinos Karmiris , Séverine Vermeire , Celine Desvignes , Nicolas Azzopardi , et al. European Journal of Clinical Pharmacology, 2015, 71 (9), pp.1155-1157. ⟨10.1007/s00228-015-1892-1⟩ Article dans une revue hal-01769822v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study Benoit Coudert , Jean-Yves Pierga , Marie-Ange Mouret-Reynier , Kaldoun Kerrou , Jean-Marc Ferrero , et al. EClinicalMedicine, 2020, 28, pp.100566. ⟨10.1016/j.eclinm.2020.100566⟩ Article dans une revue hal-03244169v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab D. Ternant , N. Ceze , F. Piller , D. Degenne , E. Dorval , et al. Fundamental & Clinical Pharmacology, 2009, 23, pp.23-23 Article dans une revue hal-00616413v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Therapeutic antibodies in ophthalmology Old is new again Charlotte Magdelaine-Beuzelin , Coralie Pinault , Gilles Paintaud , Herve Watier mAbs, 2010, 2 (2), pp.176-180. ⟨10.4161/mabs.2.2.11205⟩ Article dans une revue hal-00616362v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics David Ternant , Nicolas Ceze , Thierry Lecomte , Danielle Degenne , Anne-Claire Duveau , et al. Ther. Drug Monit., 2010, 32 (5), pp.647-652 Article dans une revue hal-00616329v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab Agnes Maillet , Laurent Guilleminault , Nicolas Azzopardi , Jerome Montharu , Laurent Vecellio , et al. Journal of Thoracic Oncology, 2009, 4 (9), pp.S600-S600 Article dans une revue hal-00616858v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration David Ternant , Christophe Passot , Alexandre Aubourg , Philippe Goupille , Celine Desvignes , et al. Clinical Pharmacokinetics, 2018, 57 (9), pp.1173-1184. ⟨10.1007/s40262-017-0621-6⟩ Article dans une revue hal-02372850v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans David Ternant , Nicolas Azzopardi , William Raoul , Theodora Bejan-Angoulvant , Gilles Paintaud Clinical Pharmacokinetics, In press, ⟨10.1007/s40262-018-0680-3⟩ Article dans une revue hal-01821717v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis Gilles Paintaud , Jean-Camille Meric , Denis Mulleman , Emilie Ducourau , Charlotte Magdelaine-Beuzelin , et al. Fundamental & Clinical Pharmacology, 2009, 23, pp.29-29 Article dans une revue hal-00616867v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Infliximab pharmacokinetics in inflammatory Bowel disease patients David Ternant , Alexandre Aubourg , Charlotte Magdelaine-Beuzelin , Danielle Degenne , Herve Watier , et al. Ther. Drug Monit., 2008, 30 (4), pp.523-529 Article dans une revue hal-00616549v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face A. Rosen , S. Thimon , David Ternant , M. C. Machet , Gilles Paintaud , et al. British Journal of Dermatology, 2010, 163 (1), pp.225-227 Article dans une revue hal-00616757v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. M. Roland , C. Barbet , Gilles Paintaud , E. Diot , Jm Halimi , et al. Congrès P2T (12ème congrès annuel de la Société Française de Pharmacologie et de Thérapeutique),, Apr 2008, Clermont-Ferrand, France. pp.88 Communication dans un congrès hal-00320397v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		A 3-week course of 80 mg weekly administered adalimumab as a rescue therapy for patients with Crohn's disease who lost response to 40 mg weekly : relationship with adalimumab trough serum levels. Colitis Organisation Congress. Lyon, février-mars 2008. K. Karmiris , M. Noman , Gilles Paintaud , M. Ferrante , Anne-Claire Duveau , et al. 3rd congress of the European Crohn's, Mar 2008, LYON, France. pp.27 Communication dans un congrès hal-00320146v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis Frédéric Medina , Chamaida Plasencia , Philippe Goupille , Gilles Paintaud , Alejandro Balsa , et al. Therapeutic Drug Monitoring, 2017, 39 (4), pp.360-363. ⟨10.1097/FTD.0000000000000400⟩ Article dans une revue hal-01980745v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		PO-0702: Phase I trial evaluating panitumumab in combination with chemoradiotherapy for anal cancers V. Vendrely , C. Lemanski , E. Le Prise , E. Maillard , X. Mirabel , et al. ESTRO 36, May 2017, Vienne, Austria. , Radiotherapy and Oncology, 123 (Supplement 1), pp.S367 - S368, 2017, ESTRO 36, May 5-9, 2017, Vienna, Austria. ⟨10.1016/S0167-8140(17)31139-8⟩ Poster de conférence hal-01685153v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Mise au point d'une méthode de dosage sérique du cétuximab appliquée au suivi thérapeutique des patients traités. Nicolas Cézé , David Ternant , F. Piller , Danielle Degenne , Hervé Watier , et al. Journées Francophones de Pathologie Digestive, Paris, mars 2008., Mar 2008, PARIS, France. pp.51 Communication dans un congrès hal-00320376v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Nonlinear pharmacokinetics of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis. Denis Mulleman , Amina Bensalem , David Ternant , Gilles Paintaud , Divi Cornec , et al. EULAR 2019, Jun 2019, MADRID, Spain Poster de conférence hal-02151041v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice Christophe Arnoult , Guillaume Brachet , Diana Cadena Castaneda , Nicolas Azzopardi , Christophe Passot , et al. Journal of Immunology, 2017, 199 (2), pp.418-424. ⟨10.4049/jimmunol.1601246⟩ Article dans une revue hal-02019721v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		An enzyme-linked immunosorbent assay for therapeutic drug monitoring of Cetuximab David Ternant , Nicolas Cézé , F. Piller , Danielle Degenne , E. Dorval , et al. Fundam Clin Pharmacol, Apr 2009, MARSEILLE, France Communication dans un congrès hal-00375861v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation Xavier de Lamballerie , Guillaume Martin-Blondel , Axelle Dupont , Jacques Izopet , France Mentré , et al. Journal of Infection, 2023, 86 (1), pp.66-117. ⟨10.1016/j.jinf.2022.10.006⟩ Article dans une revue hal-04027487v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Tumor burden influences exposure and response to rituximab : pharmacokinetic - pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20 David Dayde , David Ternant , Marc Ohresser , S. Lerondel , S. Pesnel , et al. Blood, 2009, 113, pp.3765-3772 Article dans une revue hal-00422647v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients Morgane Caulet , Thierry Lecomte , Olivier Bouché , Jérôme Rollin , Valérie Gouilleux-Gruart , et al. Clinical Pharmacokinetics, 2016, 55 (11), pp.1381 - 1394. ⟨10.1007/s40262-016-0406-3⟩ Article dans une revue hal-01769811v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis Amina Bensalem , Denis Mulleman , Gilles Thibault , Nicolas Azzopardi , Philippe Goupille , et al. British Journal of Clinical Pharmacology, 2019, ⟨10.1111/bcp.14102⟩ Article dans une revue hal-02376303v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Gota et al. on their article “the pharmacokinetics of Reditux™, a biosimilar of rituximab” Mira Tout , Christophe Passot , Guillaume Cartron , Gilles Paintaud , David Ternant Cancer Chemotherapy and Pharmacology, 2016, 78 (6), pp.1317 - 1318. ⟨10.1007/s00280-016-3176-6⟩ Article dans une revue hal-01818536v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More
		Body surface area, erythrocyte sedimentation rate, methotrexate and antibodies to infliximab influence the pharmacokinetics of infliximab in rheumatoid arthritis Gilles Paintaud , Emilie Ducourau , David Ternant , A. Gorondan , B. Legoff , et al. Fundamental & Clinical Pharmacology, 2010, 24, pp.51-51 Article dans une revue hal-00616804v1	Envoyer sur ORCID Exporter BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite Export avancé Partager Gmail Facebook X LinkedIn More

Filtrer vos résultats

Infliximab concentration is predictive of control of disease activity and maintenance of treatment in rheumatoid arthritis.

Adalimumab trough serum levels and clinical response in a single-center cohort of inflammatory bowel disease patients: Can trough serum levels serve as a predictor for Future Loss of Response?

Brief Report: Relationship Between Serum Infliximab Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis

A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)

Development and validation of an enzyme-linked immunosorbent assay to measure adalimumab concentration

Pharmacokinetics of adalimumab in Crohn’s disease

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab

Therapeutic antibodies in ophthalmology Old is new again

An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics

Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab

Model-Based Therapeutic Drug Monitoring of Infliximab Using a Single Serum Trough Concentration

Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis

Infliximab pharmacokinetics in inflammatory Bowel disease patients

Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face

Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study.

A 3-week course of 80 mg weekly administered adalimumab as a rescue therapy for patients with Crohn's disease who lost response to 40 mg weekly : relationship with adalimumab trough serum levels. Colitis Organisation Congress. Lyon, février-mars 2008.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis

PO-0702: Phase I trial evaluating panitumumab in combination with chemoradiotherapy for anal cancers

Mise au point d'une méthode de dosage sérique du cétuximab appliquée au suivi thérapeutique des patients traités.

Nonlinear pharmacokinetics of rituximab in anti-neutrophil cytoplasmic antibody associated vasculitis.

Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of Cetuximab

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation

Tumor burden influences exposure and response to rituximab : pharmacokinetic - pharmacodynamic modelling using a syngeneic bioluminescent murine model expressing human CD20

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis

Gota et al. on their article “the pharmacokinetics of Reditux™, a biosimilar of rituximab”

Body surface area, erythrocyte sedimentation rate, methotrexate and antibodies to infliximab influence the pharmacokinetics of infliximab in rheumatoid arthritis